Tumor Treatment Field Therapy (TTFT) Final LCD (L34823) and Response to Comments (RTC) Article Published - JA DME

Joint DME MAC Publication

Today, the DME MACs published the Tumor Treatment Field Therapy (TTFT) Final LCD (L34823) and LCD-related Policy Article (PA) (A52711).  The policy extends coverage of TTFT as a treatment option for Medicare beneficiaries with newly diagnosed glioblastoma multiforme (GBM).  The posting of the final LCD marks the beginning of the 45-day notice period.  The final LCD will be effective for claims with dates of service on or after September 1, 2019.

The DME MACs have also posted a response to all written comments received during the comment period, in a Response to Comments (RTC) Article (A56688).

Please refer to each DME MAC web site for additional information about policy development and copies of the final LCD.

• Jurisdiction A
• Jurisdiction B
• Jurisdiction C
• Jurisdiction D